The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting a major shift in medical diagnostics, C2N Diagnostics has secured the first-ever U.S. insurance coverage for its PrecivityAD2 Alzheimer's diagnostic blood test. According to reports, Anthem Blue Cross and Blue Shield will begin covering the test for eligible patients starting October 1. This milestone aims to improve patient access to non-invasive diagnostics, marking a significant transition toward blood-based testing in clinical practice as an alternative to more invasive or costly traditional methods.
This development comes amid intensifying competition in the Alzheimer's diagnostic market, with peers like Quest Diagnostics and Labcorp also advancing blood-based screening tools to bypass expensive PET scans. Per market data, securing coverage from a major insurer like Anthem is a critical step for the commercial viability of biotech innovations, often serving as a catalyst for broader industry adoption. Recent clinical studies suggest that high-performance blood tests can match the accuracy of traditional cerebrospinal fluid analysis, potentially lowering long-term healthcare costs.
Sign in to access this content
Sign InLooking ahead, investors are monitoring how quickly other major insurers will follow Anthem's lead in validating blood-based diagnostics. While specific instrument prices remain unavailable for these private entities, market participants are eyeing upcoming catalysts such as the U.S. ISM Services PMI data (as of July 6, 2026) for insights into healthcare service spending. Additionally, the broader biotech funding environment will be sensitive to central bank signals, including the scheduled speech by Fed Governor Bowman on July 7.